Published reports on the relationship between GSTM1 gene polymorphisms and prostate cancer risk are heterogeneous in their conclusions, and the significance of these polymorphisms is still debated. This meta-analysis was performed to attempt to combine comparable studies, thereby increasing sample size and statistical significance in order to obtain a better evaluation of the association between GSTM1 polymorphisms and prostate cancer risk. The association investigations were identified from PubMed, Cochrane Library, and China Biological Medicine Database on March 1, 2014. Forty-three reports were recruited into this meta-analysis that contained data from 6741 patients and 9053 controls. There was a marked association between the GSTM1 null genotype and prostate cancer risk in the overall population (odds ratio ¼ 1.39, 95% confidence interval: 1.21-1.60, P < .00001), caucasians (odds ratio ¼ 1.48, 95% confidence interval: 1.23-1.79, P < .0001) and Asians (odds ratio ¼ 1.62, 95% confidence interval: 1.16-2.27, P ¼ .005). However, the GSTM1 null genotype was not associated with prostate cancer risk in Africans (odds ratio ¼ 0.77, 95% confidence interval: 0.53-1.13, P ¼ 0.19) and African Americans (odds ratio ¼ 1.00, 95% confidence interval: 0.69-1.45, P ¼ 0.99). In conclusion, GSTM1 null genotype was a risk factor to predict the prostate cancer risk in the overall population, Caucasians, and Asians. Although compelling, limitations inherent to meta-analysis, study design of the individual studies, and most importantly, possible gene-gene and gene-environment interactions, as well as the potential involvement of glutathione S-transferases in multiple cellular processes make drawing definite conclusions difficult.
Introduction
Prostate cancer is a malignant disease of the prostate that predominantly affects males above the age of 50 and generally requires a long period for development from onset to clinical manifestation. [1] [2] [3] Prostate cancer may display periods of latency of up to 20 years in which it remains organ confined. 4 Indeed, autopsy studies in men with various ethnic backgrounds who died of causes unrelated to prostate cancer showed that *20% to 30% of men in their 50s and *70% to 80% of men in their 70s had prostate cancer lesions , [4] [5] and that this incidence increased with age. 4 Global incidence rates vary widely, with lower rates in Asia compared with Europe, Australia, and the United States. 1, 6 Overall, prostate cancer is the sixth major cause of cancer-related death in males and the second in the United States. 1, 6 Although prostate cancer lesions can remain in situ for long periods of time, more aggressive forms are known and when metastasis occurs, predominantly lymph nodes and bones are affected with detrimental results. Overall, the single most significant risk factor for prostate cancer is advanced age; although, prostate cancer cannot simply be considered an aging by-product. Other risk factors include obesity, hypertension, environmental stressor, and genetic factors, including race, specific gene variants, and familial predisposition (males with a first-degree relative with prostate cancer have at least twice the risk of developing prostate cancer [7] [8] ). Nonetheless, the behavior of this tumor type remains difficult to predict 9 and welldocumented diagnostics for determining prostate cancer risk are scare.
In prostate cancer, aging-associated gene expression changes have been described that include genes involved in oxidative stress, inflammation, and senescence, [10] [11] [12] particularly in the prostate stroma. Gene variations in these genes are implicated to increase the susceptibility to prostate cancer. Glutathione-S-transferases (GSTs) are crucial enzymes of phase II detoxification ( Figure 1A ) that counteract the damaging effects of environmentally and endogenously produced electrophilic substances through nucleophilic attack by glutathione to an electrophilic carbon [13] [14] [15] and additionally act as modulators of signal transduction pathways in response to stress, growth factors, and DNA damage, including Jun N-terminal kinase, apoptosis-signal-regulating kinase 1, Fanconia anemia group C protein, and tissue transglutaminase 2. 14, 16 Increasingly, GST genes are being recognized as polymorphic, 17 and particularly alleles that cause impaired catalytic activity may be associated with increased sensitivity to toxic compounds ( Figure 1A) .
Glutathione S-transferases of the Mu class consist of 5 isoforms (5'-GSTM4-GSTM2-GSTM1-GSTM5-GSTM3-3') located in a 20 kb cluster on chromosome 1 (1p13.3), 18 and polymorphisms particularly in GSTM1 have been reported. Deletion (null genotype) of GSTM1 results in the complete absence of GST enzymatic activity, and individuals homozygous for this deletion are thought to have an increased risk for developing malignancies [19] [20] [21] due to a reduced toxin/carcinogen detoxifying capacity. Several epidemiologic studies were conducted over the past decades to determine the association of GSTM1 gene polymorphisms with prostate cancer risk. However, the available evidence is inconclusive, predominantly due to small sample sizes and/or incongruity among investigations. We performed this meta-analysis to investigate to what extent the GSTM1 gene polymorphism is associated with the risk of developing prostate cancer by carefully scrutinizing the available data in reported studies, thereby increasing the sample size.
Materials and Methods

Search Strategy for the Relationship Between GSTM1 Gene Polymorphism and Prostate Cancer Risk
Relevant studies were extracted from the electronic databases of PubMed, Cochrane Library, and China Biological Medicine Database on March 1, 2014. The retrieval strings entered into these databases were ''(Glutathione S-transferase M1 OR GSTM1 OR GSTM)AND (prostate cancer OR prostatic cancer OR prostate carcinoma OR prostatic carcinoma)''. Additional reports were identified by scrutinizing the references cited in the recruited articles. 
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(2) there had to be at least 2 comparison groups (prostate group vs control group); and (3) the investigation should provide data on the GSTM1 genotype distribution.
Exclusion criteria. (1) Review articles and editorials; (2) case reports; (3) preliminary result not on GSTM1 gene polymorphism or outcome; (4) investigation of the role of GSTM1 gene expression related to disease; and (5) if multiple publications for the same data from the same study group occurred, we only recruited the later dated paper into our final analysis.
Data Extraction and Synthesis
The following information from each eligible study was extracted independently by 2 investigators (Tian-Biao Zhou and Zong-Pei Jiang): first author's surname, year of publication, location of the study performed, ethnicity, control source of the control group, and the number of cases and controls for the GSTM1 genotype. The results were compared, and disagreement was resolved by discussion (Miao-Fang Huang and Gregor P.C. Drummen).
Statistical Analysis
Cochrane Review Manager Version 5 (Cochrane Library, United Kingdom) was used to calculate the available data from each study. The pooled statistic was counted using the fixed effects model, but a random effects model was used when the P value of heterogeneity test was less than.1. 22 Results were expressed with odds ratios (OR) for dichotomous data, and 95% confidence intervals (CI) were calculated. P < .05 was required for the pooled OR to be statistically significant. 23 26 were used for exploring publication bias (P < 0.1 was considered significant), when the number of the included studies was larger than 10.
Results
Study Characteristics
A total of 77 studies were retrieved from the databases independently by 2 investigators (Tian-Biao Zhou and Zong-Pei Jiang). The results were compared, and disagreement over 3 articles was resolved by discussion (Miao-Fang Huang and Gregor P.C. Drummen). The data were entered into Cochrane Review Manager Version 5 to calculate the available data, and the results were shown to be comparable. An overview of the selection procedure is presented in Figure 1B . Forty-three studies reporting on the relationship between GSTM1 gene polymorphism and prostate cancer susceptibility met our criteria and were recruited into this meta-analysis; all the reports were published in English. The data of interest were extracted as summarized in Table 1 . The included studies contained a total of 6741 patients with prostate cancer and 9053 controls. The average distribution frequency of the GSTM1 null genotype in the prostate cancer group was 49.79%, and the average frequency in the control group was 41.56%. The average distribution frequency in case group was higher than that in control group (case/control ¼ 1.20). The average distribution of the GSTM1 null genotype frequency in caucasians was 49.01% in cases and 39.53% for controls. Furthermore, the average distribution frequency of the GSTT1 null genotype was 58.27% and 46.65% in Asian patients with prostate cancer and in controls, respectively. In both Asians and Caucasians, the average distribution frequency of the GSTT1 null genotype was significantly higher in the case group compared with the control (caucasians: case/control ¼ 1.24; Asians: case/control ¼ 1.25).
Association of GSTM1 Null Genotype With Prostate Cancer Susceptibility in Various Populations
Evaluation of the various populations in this meta-analysis showed particular trends regarding prostate cancer risk and the presence of the GSTM1 null genotype. In the overall population, the presence of the GSTM1 null genotype was distinctly associated with prostate cancer risk (OR ¼ 1.39, 95% CI: 1.21-1.60, P < .00001; Figure 2 and Table 2 ). An equal association between the GSTM1 null genotype and prostate cancer could be established for caucasians (OR ¼ 1.48, 95% CI: 1.23-1.79, P < .0001; Figure 3 and Table 2 ) and Asians (OR ¼ 1.62, 95% CI: 1.16-2.27, P ¼ .005; Table 2 ). Conversely, neither for Africans nor African Americans could such an association be established (Africans: OR ¼ 0.77, 95% CI: 0.53-1.13, P ¼ .19; Table 2 ; African Americans: OR ¼ 1.00, 95% CI: 0.69-1.45, P ¼ .99; Table 2 ).
Sensitivity Analysis
Sensitivity analysis is generally used to determine if results are sensitive to restrictions on the data and if the data are consistent in order to provide stronger evidence of an observed effect. Therefore, the data included in this meta-analysis was subjected to sensitivity analysis.
Sensitivity analysis for the relationship between the GSTM1 null genotype and prostate cancer risk was performed according to the source of the controls (healthy vs hospital) and according to sample size of case (<100 vs 100). In both analyses, a clear association between the GSTM1 null genotype and prostate cancer risk could be established. Overall, no significant deviations were found between nonsensitivity and sensitivity analyses (Table 2) , and the results strengthen the fact that the presence of the GSTM1 null genotype potentially increases prostate cancer risk.
Evaluation of Publication Bias
Publication bias was tested, and publication bias was established for the overall population (Begg P ¼ .004, funnel plot presented in Figure 4 ; Egger P ¼ .003), caucasians (Begg P ¼ .016, Egger P ¼ .006), sample size of case or control (100; Begg P ¼ .042, Egger P ¼ .016), sample size of case or control (<100; Begg P ¼ .592, Egger P ¼ .848), control from population based (Begg P ¼ .012, Egger P ¼ .005), and control from hospital based (Begg P ¼ .392, Egger P ¼ .532).
Discussion
Even though genetic factors have been implicated in the etiology of prostate cancer, these have not yet been fully elucidated and are still the focus of intense research. Some investigations show that testing for particular genetic aberrations can be used as diagnostic markers in particular forms of cancer, [70] [71] for example, EGFR, Kras, JAK2 and p53 mutations, ALK rearrangements, and 18q-loss of heterozygosity/deleted in colorectal cancer tests are routinely requested by community oncologists. 
R E T R A C T E D
Currently available preventive screening strategies include molecular testing for prostate-specific antigen and digital rectal examination, but there is a clear lack of suitable genetic markers. Furthermore, recent investigations on the efficacy of current preventive screening show no mortality benefit from screening. 72 The central role that GSTs play in counteracting exogenous and endogenous stressors makes the genes that code for them important candidates as potential predictive markers for prostate cancer. However, the available literature is replete with correlative epidemiological reports on GST gene aberrations and cancer risk, but these generally suffer from small sample sizes that preclude definitive conclusions of cause and effect between GST expression and cancer incidence. Meta-analyses aim to overcome these limitations by combining comparable studies, thereby increasing sample size and statistical significance. In the current meta-analysis, we investigated the significance of the GSTM1 null genotype in relation to prostate cancer, and whether the GSTM1 null genotype might be used as an indicator to predict prostate cancer risk. The results showed that the average distribution frequency of the GSTM1 null genotype in cases was 1.20-fold increased compared with the control group. For the overall population, caucasians and Asians, a positive correlation with prostate cancer risk could be established. Although the number of included studies for the overall population and caucasians was large and statistically relevant, the data for these populations suffered from publication bias. We calculated the pooled OR according to the fixed model and found that the results were similar to those from the random model.
No association could be established between the GSTM1 null genotype and prostate cancer risk in African and African American populations. However, the number of included studies for these ethnic groups was relatively small (2 and 2 studies 
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Technology in Cancer Research & Treatment 15 (6) for African and African American versus 27 and 9 studies for caucasians and Asians), and the results may therefore be less robust. More prospective studies in African and African American populations should be performed to evaluate if indeed an association between the GSTM1 null genotype and prostate cancer risk exists in these ethnic groups.
In the sensitivity analysis according to the source of the controls and the sample size of case, we found that the results were similar to those obtained from nonsensitivity analysis, and the results established that the GSTM1 null genotype increased the risk of developing prostate cancer. Though there was a significant publication bias in the analysis of sample size of case ( 100), control from population based, the fixed effects and random effects models showed similar results. We therefore consider the established association to be significant.
Similar meta-analyses reported in the literature showed varying results. Ntais et al 73 conducted a meta-analysis that included 11 studies and reported that the GSTM1 null genotype was not associated with prostate cancer risk. Conversely, Mo and co-workers 74 reported the opposite from a meta-analysis that included 29 studies. We show that the presence of the GSTM1 null genotype in the overall population, caucasians, or Asians significantly increases the risk of developing prostate cancer. Our analysis included 43 studies with a sufficiently large data set. Consequently, we consider our results to bear a higher statistical significance, and the analysis implicates the GSTM1 null genotype in prostate cancer risk. Nonetheless, our results should still be interpreted with care. As phase II detoxifying enzymes, GSTs are likely to act in conjunction with other enzymes rather than isolated. Furthermore, there is increasing evidence that GSTs play important roles in intracellular signaling events, such as kinase signaling, 14 and in glutathionylation, 75 which indicates that their cellular function surpasses their catalytic properties. Consequently, any statistical correlations are likely to be oversimplistic. In order to obtain a better insight, multivariant analysis of other enzymes (and genes) should be taken into account. The same goes for environmental factors. Furthermore, the studies scrutinized for our meta-analysis showed significant heterogeneity for the GSTM1 polymorphism despite subgroup analysis. This heterogeneity among the included studies points toward other potential confounding factors such as selection bias, genotyping errors, environmental factors, and multilocus phenomena, [76] [77] as stated above. Nonetheless, sensitivity analysis showed no significant effects on the overall OR estimates. Additionally, publication bias was established, which leads to distortion of observations because the published studies may not be truly representative of all available data (positive results are more likely of being published). Our meta-analysis only contained published data. Overall, these inconsistencies show the limitations of single gene polymorphism studies when attempting to draw definite conclusions on disease risk. 
